The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Selection for time-limited & continuous therapy in CLL
Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, discusses patient selection for time-limited and continuous therapy in chronic lymphocytic leukemia (CLL). While data from the GAIA/CLL13 study (NCT02950051) has demonstrated that patients with mutated IGHV status benefit more from time-limited therapy, it has been suggested that high-risk or very high-risk patients have better responses with continuous treatment. For patients with some adverse prognostic factors, Dr Eichhorst emphasizes the importance of shared treatment decision-making. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Dr Eichhorst receives honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).
